Literature DB >> 20104161

Outcomes of gastrocnemius-soleus complex lengthening for isolated equinus contracture in children with cerebral palsy.

Chester M Tylkowski1, Mike Horan, Donna J Oeffinger.   

Abstract

BACKGROUND: The goal of the gastrocnemius-soleus complex (GSC) lengthenings in children with cerebral palsy (CP) is to achieve a plantigrade foot and normalize kinematics during gait. The study purpose was to evaluate the results of GSC lengthening for isolated equinus contracture in individuals with CP. It was hypothesized that GSC lengthenings would normalize passive ankle range of motion, kinematic, kinetic, and temporal spatial parameters.
METHODS: Gait data from 15 able-bodied participants from the laboratory normal database and passive range of motion, kinematic, kinetic, and temporal spatial gait parameters, and oxygen cost were collected and analyzed for 27 individuals with CP (36 limbs) with isolated equinus contracture who received GSC lengthenings. Data were compared between preoperative and postoperative assessments.
RESULTS: Mean age at baseline was 11.4 years (+/-3.2 y). Mean time between surgery and postoperative gait analysis was 1.3 years (+/-0.3 y). Passive range of motion measurements were obtained. Kinematic and kinetic data for the hip, knee and ankle, and temporal spatial parameters were obtained from a representative gait trial preoperatively and postoperatively. Paired t tests (P<0.05) determined whether preoperative data differed from postoperative data or from able-bodied data. The passive range of motion at the ankle was improved and normalized postoperatively. Ankle kinematics normalized without compensatory changes occurring at the knee or hip kinematics. Ankle moments and powers become more normal but did not completely normalize. Kinematics and kinetics of the hip and knee were not adversely affected. No changes in the temporal spatial data or oxygen cost occurred postoperatively.
CONCLUSIONS: These data support the finding that with appropriate patient selection isolated GSC lengthening does not result in overcorrection. LEVEL OF EVIDENCE: Retrospective comparative study; level 3.

Entities:  

Mesh:

Year:  2009        PMID: 20104161     DOI: 10.1097/BPO.0b013e3181b76a7c

Source DB:  PubMed          Journal:  J Pediatr Orthop        ISSN: 0271-6798            Impact factor:   2.324


  6 in total

1.  Short-term effect of botulinum toxin a injection on spastic equinovarus foot in cerebral palsy patients: a study using the foot pressure measurement system.

Authors:  Su Min Son; In Sik Park; Jin Sun Yoo
Journal:  Ann Rehabil Med       Date:  2015-02-28

Review 2.  Relationship between ankle function and walking ability for children and young adults with cerebral palsy: A systematic review of deficits and targeted interventions.

Authors:  Benjamin C Conner; Nushka M Remec; Cassidy M Michaels; Chase W Wallace; Emily Andrisevic; Zachary F Lerner
Journal:  Gait Posture       Date:  2021-10-25       Impact factor: 2.840

3.  Comparison of gait with and without ankle-foot orthoses after lower limb surgery in children with unilateral cerebral palsy.

Authors:  I Skaaret; H Steen; A B Huse; I Holm
Journal:  J Child Orthop       Date:  2019-04-01       Impact factor: 1.548

Review 4.  Three-Dimensional Gait Analysis in Children Undergoing Gastrocsoleus Lengthening for Equinus Secondary to Cerebral Palsy.

Authors:  Norine Ma; Nicholas Sclavos; Elyse Passmore; Pam Thomason; Kerr Graham; Erich Rutz
Journal:  Medicina (Kaunas)       Date:  2021-01-22       Impact factor: 2.430

Review 5.  Topical Review: Approach to Diagnosis and Management of the Pediatric Foot and Ankle in Cerebral Palsy Patients.

Authors:  Sean A Tabaie; Anthony J Videckis; Theodore Quan; Evan D Sheppard
Journal:  Foot Ankle Orthop       Date:  2022-04-22

Review 6.  Ankle Dorsiflexor Function after Gastrocsoleus Lengthening in Children with Cerebral Palsy: A Literature Review.

Authors:  Nicholas Sclavos; Norine Ma; Elyse Passmore; Pam Thomason; H Kerr Graham; Erich Rutz
Journal:  Medicina (Kaunas)       Date:  2022-03-02       Impact factor: 2.430

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.